DB (NO MORE THAN 150 WORDS)
Hello class! Looks like we made it to the end!
When a company like X5RL creates a breakthrough treatment, the question of whether people can afford it gets complicated fast. Technically, the public’s financial struggles aren’t X5RL’s “problem,” but it’s hard to argue they shouldn’t care. Pharmaceutical companies benefit from patents, public funding, and a lot of trust from society, so it feels reasonable to expect them to think beyond profit when the product literally saves lives (Weiss, 2021). If they ignore the fact that huge groups of people can’t access the treatment, they might make money in the short run, but they risk losing credibility and facing backlash later.
There are realworld examples that show companies can balance profit and responsibility. GSK, for instance, used tiered pricing and lowered costs for certain medications in lowincome countries. They still protected their IP, but they also made sure people who needed the drugs weren’t completely shut out (GSK, 2023). On the flip side, insulin manufacturers have been heavily criticized for keeping prices high, even though insulin is essential for survival. That situation shows how prioritizing profit too aggressively can damage a company’s reputation and even push lawmakers to step in.
For X5RL, a CSRfocused strategy could include tiered pricing, licensing the drug to generic manufacturers in poorer regions, or partnering with global health organizations to expand access. These options let the company keep earning revenue while still honoring ethical principles like fairness and beneficence (Freeman et al., 2020). At the end of the day, protecting IP and making money doesn’t have to conflict with doing the right thing. Innovation matters, but it matters a lot more when everyone can benefit from it.
LD (no more than 150 words)
The central issue is not a simple choice between profit and people; rather, it is whether innovation can be structured in a way that sustains financial incentives while honoring the broader social contract that underpins public trust in healthcare systems.
For X5RL, integrating corporate social responsibility into its intellectual property strategy does not mean sacrificing profitability. Instead, it calls for intentional design what might be described as structured differentiation. A tiered pricing model, in which higher-income markets effectively subsidize access in lower-income regions, allows the company to protect its patent rights, recover research and development investments, and fund future innovation while simultaneously expanding equitable access to treatment.
History demonstrates the consequences of failing to strike this balance. Insulin manufacturers, though operating within legal and economic frameworks that justified pricing through R&D and supply-chain costs, faced significant public backlash when price increases were perceived as limiting access to life-sustaining medication.
The result was reputational harm, regulatory scrutiny, and policy reform. These outcomes illustrate that legal compliance alone is insufficient when public health is at stake. By proactively aligning intellectual property protection with accessible pricing strategies, X5RL can position itself not only as a profitable innovator, but as a responsible steward of transformative healthcare preserving both its market leadership and its legitimacy in the eyes of society.
